Product Information
RUFINAMIDE 40 MG/ML SUSPENSION is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $0.2034 per ML under NDC 00054052863. Its NADAC has been published 298 times since Jan 20, 2021.
FDA first approved this application on Apr 23, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/mL
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00054052863
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RUFINAMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA207363FDA Approved
4/23/2019
TE Code
AB
On Market Since
11/1/2020
Price Statistics
The NADAC for RUFINAMIDE 40 MG/ML SUSPENSION has been published 298 times since Jan 20, 2021, and over the history we have for it it has declined 92.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2034 per ML |
|---|---|
| All-time high | $3.2349 (Oct 13, 2021) |
| All-time low | $0.2021 (Jul 22, 2026) |
| 52-week high | $0.3679 |
| 52-week low | $0.2021 |
| Median price | $0.6516 |
| Average price | $1.1479 |
| Largest weekly change | -53.3% (Sep 20, 2023) |
| Weeks tracked | 298 |
| Tracking since | Jan 20, 2021 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Rufinamide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RUFINAMIDE 40 MG/ML SUSPENSION?
The current National Average Drug Acquisition Cost (NADAC) for RUFINAMIDE 40 MG/ML SUSPENSION, manufactured by Hikma Pharmaceuticals USA Inc., is $0.2034 per ML (NDC 00054052863), effective Sep 30, 2026.
How has the price of RUFINAMIDE 40 MG/ML SUSPENSION changed over time?
Over the history we have for it, the NADAC for RUFINAMIDE 40 MG/ML SUSPENSION has declined 92.9%. It has been tracked across 298 weekly CMS publications since Jan 20, 2021.
What are the highest and lowest recorded NADAC prices for RUFINAMIDE 40 MG/ML SUSPENSION?
Since Jan 20, 2021, the NADAC for RUFINAMIDE 40 MG/ML SUSPENSION has ranged from a low of $0.2021 (Jul 22, 2026) to a high of $3.2349 (Oct 13, 2021), with a median of $0.6516 per ML.
Are there cheaper alternatives to RUFINAMIDE 40 MG/ML SUSPENSION?
6 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RUFINAMIDE 40 MG/ML SUSPENSION in a comparable dosage form, but none are currently priced below it.
Who manufactures RUFINAMIDE 40 MG/ML SUSPENSION?
RUFINAMIDE 40 MG/ML SUSPENSION (NDC 00054052863) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.